Details

Autor(en) / Beteiligte

• Bruce, Michael G.
• Bruden, Dana
• Hurlburt, Debby
• Zanis, Carolyn
• Thompson, Gail
• Rea, Lisa
• Toomey, Michele
• Townshend-Bulson, Lisa
• Rudolph, Karen
• Bulkow, Lisa
• Spradling, Philip R.
• Baum, Richard
• Hennessy, Thomas
• McMahon, Brian J.

Titel

Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose

Ist Teil von

• The Journal of infectious diseases, 2016-07, Vol.214 (1), p.16-22

Ort / Verlag

United States: Oxford University Press

Erscheinungsjahr

2016

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Background. The duration of protection in children and adults resulting from hepatitis B vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska Native adults and children from 15 Alaska communities aged ≥6 months using 3 doses of plasma-derived hepatitis B vaccine. Methods. Persons were tested for antibody to hepatitis B surface antigen (anti-HBs) levels 30 years after receiving the primary series. Those with levels <10 mIU/mL received 1 booster dose of recombinant hepatitis B vaccine 2–4 weeks later and were then evaluated on the basis of anti-HBs measurements 30 days after the booster. Results. Among 243 persons (56%) who responded to the original primary series but received no subsequent doses during the 30-year period, 125 (51%) had an anti-HBs level ≥10 mIU/mL. Among participants with anti-HBs levels <10 mIU/mL who were available for follow-up, 75 of 85 (88%) responded to a booster dose with an anti-HBs level ≥10 mIU/mL at 30 days. Initial anti-HBs level after the primary series was correlated with higher anti-HBs levels at 30 years. Conclusions. Based on anti-HBs level ≥10 mIU/mL at 30 years and an 88% booster dose response, we estimate that ≥90% of participants had evidence of protection 30 years later. Booster doses are not needed.